{"id":"https://genegraph.clinicalgenome.org/r/022f0247-9632-4bd1-b209-e41bb29ba5a6v1.0","type":"EvidenceStrengthAssertion","dc:description":"NHP2 ribonucleoprotein (*NHP2*) was first reported in relation to autosomal recessive dyskeratosis congenita in 2008 (Vulliamy et al., PMID 18523010). *NHP2* biallelic variant carriers present with features common to other monogenic telomere biology disorders (TBD) like: oral leukoplakia, reticular skin pigmentation, nail dystrophy, bone marrow failure, intellectual disability, and short telomeres. Variation in other telomere related genes like *TERT* and *TERC* have been shown to be related to interstitial lung disease (ILD), but to date ILD has not been observed for this gene-disease entity (PMID 38718684). Seven variants (6 missense, and 1 stop-loss extension) have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data from 3 different publications describing a total of 4 probands with ages of onset being reported in both childhood and adulthood. Additionally, 4 families have been reported with heterozygous variant carriers that have presented with features consistent with TBD. The ClinGen Interstitial Lung Disease GCEP has decided to exclude heterozygous cases from this curation due to high population frequencies and/or lack of sufficient detail regarding genotyping. If, however, more convincing data of autosomal dominant inheritance becomes available, the curated entity and classification will be revisited. This gene-disease relationship is supported by protein interaction data, a yeast model and functional alteration in non-patient cells; PMID 11160879, 11074001, 37440454). Experimental data demonstrated that variant NHP2 is related to a decrease in the expression of TERC, and that expression of variant NHP2 and interaction with NOP10 and DKC1 were reduced. The mechanism is unclear but thought to be LOF. In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Interstitial Lung Disease GCEP on the meeting date April 15, 2025(SOP 11). This gene-disease pair was originally evaluated by the General GCEP on June 1, 2017. It was reevaluated on August 1, 2025. Although additional case and experimental evidence (PMIDs: 37440454, 31985013) was published, the classification did not change.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/022f0247-9632-4bd1-b209-e41bb29ba5a6","GCISnapshot":"https://genegraph.clinicalgenome.org/r/a8fa9dcb-1cc6-43a2-8f86-e6cea0e6fce2","calculatedEvidenceStrength":"Limited","contributions":[{"agent":"https://genegraph.clinicalgenome.org/agent/10026","role":"SecondaryContributor"},{"id":"https://genegraph.clinicalgenome.org/r/a8fa9dcb-1cc6-43a2-8f86-e6cea0e6fce2_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10138","date":"2025-08-01T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/a8fa9dcb-1cc6-43a2-8f86-e6cea0e6fce2_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10138","date":"2025-08-01T15:52:24.234Z","role":"Publisher"}],"curationReasons":["RecurationNewEvidence"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8fa9dcb-1cc6-43a2-8f86-e6cea0e6fce2_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8fa9dcb-1cc6-43a2-8f86-e6cea0e6fce2_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c69deeab-006d-4c0e-ad0d-75792552b29f","type":"EvidenceLine","dc:description":"Default score awarded since human TERC and NHP2 were introduced in to yeast and showed the same reduction in TERC expression observed in human cell lines","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/979545c2-a84f-4828-a6aa-4cc0991ec951","type":"Finding","dc:description":"NHP2 interacts with H/ACA box containing RNAs, which describes TERC, the template for adding TTAGGG repeats to the ends of telomeres and the availability of mature TERC is reduced when there are NHP2 LOF variants or loss of expression due to more damaging variation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11160879","rdfs:label":"Human NHP2/TERC yeast model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a8fa9dcb-1cc6-43a2-8f86-e6cea0e6fce2_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0f0dba0e-d2d7-45c9-a88f-0bdd3b4ed4eb","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97b25505-7cf0-498b-831a-a39059649bb2","type":"Finding","dc:description":"NHP2 was shown to coimmunoprecipitate H/ACA box containing snoRNAs U17 and U19 in addition to TERC. TERC has been curated to have a definitive relationship to telomere biology disease leading to many overlapping phenotypic features between TERC and NHP2 variant carriers","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11074001","rdfs:label":"NHP2 interaction with TERC","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7d65df12-8434-4f54-baf0-f65d922c415d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6d2544fc-0eeb-451b-bbde-e3e54342631c","type":"Finding","dc:description":"DKC1 has been cuarated to have a definitive gene-disease relationship with dyskeratosis congenita, a form of TBD and NOP10 is also asserted to be associated with TBD in the literature. In cell culture, the association between variant NHP2 and DKC1/NOP10 is reduced relative to WT NHP2. Further, the reduced association is observed to lead to increased degradation of variant NHP2 by the proteasome, leading to decreased levels of available protein.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37440454","rdfs:label":"Disrupted association with NOP10 and DKC1","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/a8fa9dcb-1cc6-43a2-8f86-e6cea0e6fce2_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/977e442f-78e6-4409-82a7-8c21b86945b1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2a71997-5b69-4873-a939-612335f2f46e","type":"EvidenceLine","dc:description":"Functional assay performed in patient cells so it is not clear that both variants contribute to the observation as opposed to one variant being the sole driver of the phenotype - gnomAD v4.1 Grpmax FAF 0.000002470","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2a71997-5b69-4873-a939-612335f2f46e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient cells show reduced levels of NHP2 and TRAP assay of telomerase activity is reduced compared to controls","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/f2a71997-5b69-4873-a939-612335f2f46e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31985013","allele":{"id":"https://genegraph.clinicalgenome.org/r/484ec577-fac1-4e5d-954d-92475ebd4d16","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017838.4(NHP2):c.259C>T (p.Pro87Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3589195"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/93fd8a6f-bcf9-4862-95f9-40e449923e0c","type":"EvidenceLine","dc:description":"Functional assay performed in patient cells so it is not clear that both variants contribute to the observation as opposed to one variant being the sole driver of the phenotype - gnomAD v4.1 Popmax AF 0.0000008475 (EnF)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/93fd8a6f-bcf9-4862-95f9-40e449923e0c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient cells show reduced levels of NHP2 and TRAP assay of telomerase activity is reduced compared to controls","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/93fd8a6f-bcf9-4862-95f9-40e449923e0c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31985013","allele":{"id":"https://genegraph.clinicalgenome.org/r/398b1aa4-ab02-4462-9945-7b077d97e297","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017838.4(NHP2):c.182G>C (p.Arg61Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA362392541"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/977e442f-78e6-4409-82a7-8c21b86945b1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31985013","rdfs:label":"Beynelles_Family1Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/484ec577-fac1-4e5d-954d-92475ebd4d16"},{"id":"https://genegraph.clinicalgenome.org/r/398b1aa4-ab02-4462-9945-7b077d97e297"}],"detectionMethod":"Unsure if proband variant was confirmed by Sanger but family members were genotyped for the index case variant by Sanger","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Hb: 11.9 g/dL, MCV: 88 fl, Platelets: >150 G/L, Lymphocytes: 1 G/L","phenotypes":["obo:HP_0000519","obo:HP_0031413","obo:HP_0001321","obo:HP_0008404","obo:HP_0007427","obo:HP_0002015","obo:HP_0000252","obo:HP_0001511","obo:HP_0002745","obo:HP_0004791","obo:HP_0001888"],"previousTesting":true,"previousTestingDescription":"Authors describe an NGS panel approach for variant screen and targeted genes described as being implicated in telomere maintenance","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/93fd8a6f-bcf9-4862-95f9-40e449923e0c_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f2a71997-5b69-4873-a939-612335f2f46e_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/0d46daf2-00fb-4f2d-9b15-211bd962891e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c2107c70-309d-4378-8f6d-d274d21416fd","type":"EvidenceLine","dc:description":"gnomAD v4.1 0.0000008475","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c2107c70-309d-4378-8f6d-d274d21416fd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In cells where NHP2 expression is knocked down using siRNA, TERC expression drops and is rescued by complimentation of WT NHP2 but not variant NHP2 - In PMID 20008900 Tyr139His was unable to form a tetramer with NOP10, NAF1, and DKC1 unlike WT NHP2","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c2107c70-309d-4378-8f6d-d274d21416fd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18523010","allele":{"id":"https://genegraph.clinicalgenome.org/r/2219965f-b0f3-46fb-b445-718c3164eaa4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017838.4(NHP2):c.415T>C (p.Tyr139His)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4280"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/0d46daf2-00fb-4f2d-9b15-211bd962891e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18523010","rdfs:label":"Vulliamy 2008 Individual 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":22,"allele":{"id":"https://genegraph.clinicalgenome.org/r/2219965f-b0f3-46fb-b445-718c3164eaa4"},"detectionMethod":"From paper: \"The coding sequence of the GAR1 and NHP2 genes,\ncomprising seven and four exons, respectively, was amplified in standard\nPCRs (ABgene) from genomic DNA prepared from peripheral blood using\nDNA extraction kits (Gentra). Sequences of primers used in these PCRs are\ngiven in Table S2. The resulting fragments were screened for mutation by\ndenaturing high-performance liquid chromatography on the WAVE DNA\nfragment analysis system (Transgenomic).\"","firstTestingMethod":"PCR","phenotypeFreeText":"From the paper: \"Age-adjusted telomere length measurements show\nthat the patients lie outside the normal range and are comparable\nwith patients with dyskerin mutations (Fig. 3B).\"","phenotypes":["obo:HP_0001873","obo:HP_0002514","obo:HP_0005390","obo:HP_0000029","obo:HP_0001249","obo:HP_0001394","obo:HP_0008897","obo:HP_0008404"],"previousTesting":true,"previousTestingDescription":"As part of the Dyskeratosis Congenita Registry the proband was likely screened for variation in TERT and TERC","secondTestingMethod":"Genotyping","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/c2107c70-309d-4378-8f6d-d274d21416fd_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/ae741370-2c38-4eb0-b0be-cbf1ad00043d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/85cb2561-aa4f-497b-95d2-b3c04854328d","type":"EvidenceLine","dc:description":"gnomAD v4.1 0.000001240","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/85cb2561-aa4f-497b-95d2-b3c04854328d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NHP2 KO HeLa cells when complemented with the NHP2 variant did not fully recover TERC expression or telomerase activity relative to WT","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/85cb2561-aa4f-497b-95d2-b3c04854328d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37440454","allele":{"id":"https://genegraph.clinicalgenome.org/r/c76c6b3c-07b5-4ad6-8fca-623b9106b88e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017838.4(NHP2):c.131C>T (p.Thr44Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA362392817"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9b4710a5-e917-4935-b683-6c6d84e9b380","type":"EvidenceLine","dc:description":"gnomAD v4.1 0.00003178","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9b4710a5-e917-4935-b683-6c6d84e9b380_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NHP2 KO HeLa cells when complemented with the NHP2 variant did not fully recover TERC expression or telomerase activity relative to WT","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/9b4710a5-e917-4935-b683-6c6d84e9b380_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37440454","allele":{"id":"https://genegraph.clinicalgenome.org/r/407d2f6f-1f95-4cbb-a104-36f970386c0e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017838.4(NHP2):c.115G>A (p.Ala39Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3589283"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ae741370-2c38-4eb0-b0be-cbf1ad00043d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37440454","rdfs:label":"MaliÅ„ski_Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":38,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/407d2f6f-1f95-4cbb-a104-36f970386c0e"},{"id":"https://genegraph.clinicalgenome.org/r/c76c6b3c-07b5-4ad6-8fca-623b9106b88e"}],"detectionMethod":"WGS identified variation in NHP2 were not confirmed by Sanger and no indication that parents were genotyped","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0031688","obo:HP_0005528","obo:HP_0031689","obo:HP_0012126","obo:HP_0002863","obo:HP_0002216","obo:HP_0002745","obo:HP_0001903","obo:HP_0008404","obo:HP_0031413"],"previousTestingDescription":"TERT and TERC screened by Sanger followed by WGS analysis but without Sanger confirmation","secondTestingMethod":"Whole genome shotgun sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/9b4710a5-e917-4935-b683-6c6d84e9b380_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/85cb2561-aa4f-497b-95d2-b3c04854328d_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/0065ffb9-b528-485e-aedd-5060b4292944_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0dbbdd13-d0ce-4056-adb8-1eb0b0f10dcb","type":"EvidenceLine","dc:description":"gnomAD v4.1 0.0000008475","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0dbbdd13-d0ce-4056-adb8-1eb0b0f10dcb_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In PMID 20008900 Val126Met was unable to form a tetramer with NOP10, NAF1, and DKC1 unlike WT NHP2","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0dbbdd13-d0ce-4056-adb8-1eb0b0f10dcb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18523010","allele":{"id":"https://genegraph.clinicalgenome.org/r/3c48cdab-9f6b-4f1c-b4a3-8ff4970f2816","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017838.4(NHP2):c.376G>A (p.Val126Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4281"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6e80232e-66b4-4582-820d-d48ea09a610c","type":"EvidenceLine","dc:description":"absent from gnomAD v4.1","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6e80232e-66b4-4582-820d-d48ea09a610c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18523010","allele":{"id":"https://genegraph.clinicalgenome.org/r/2b5bd361-a18f-4bb2-a905-9512eb3309fb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_017838.4(NHP2):c.460T>A (p.Ter154ArgextTer51)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4282"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/0065ffb9-b528-485e-aedd-5060b4292944","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18523010","rdfs:label":"Vulliamy 2008 Individual 2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/3c48cdab-9f6b-4f1c-b4a3-8ff4970f2816"},{"id":"https://genegraph.clinicalgenome.org/r/2b5bd361-a18f-4bb2-a905-9512eb3309fb"}],"detectionMethod":"From the paper: \"The coding sequence of the GAR1 and NHP2 genes,\ncomprising seven and four exons, respectively, was amplified in standard\nPCRs (ABgene) from genomic DNA prepared from peripheral blood using\nDNA extraction kits (Gentra). Sequences of primers used in these PCRs are\ngiven in Table S2. The resulting fragments were screened for mutation by\ndenaturing high-performance liquid chromatography on the WAVE DNA\nfragment analysis system (Transgenomic).\"","firstTestingMethod":"PCR","phenotypeFreeText":"From paper: \"Age-adjusted telomere length measurements show\nthat the patients lie outside the normal range and are comparable\nwith patients with dyskerin mutations (Fig. 3B).\"","phenotypes":["obo:HP_0007427","obo:HP_0002745","obo:HP_0005528","obo:HP_0001876","obo:HP_0008404"],"previousTesting":true,"previousTestingDescription":"As part of the Dyskeratosis Congenita Registry the proband was likely screened for variation in TERT and TERC","secondTestingMethod":"Genotyping","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/0dbbdd13-d0ce-4056-adb8-1eb0b0f10dcb_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6e80232e-66b4-4582-820d-d48ea09a610c_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":2.8}],"evidenceStrength":"Limited","sequence":10925,"specifiedBy":"GeneValidityCriteria11","strengthScore":5.8,"subject":{"id":"https://genegraph.clinicalgenome.org/r/nL9f3WAaSLU","type":"GeneValidityProposition","disease":"obo:MONDO_0013519","gene":"hgnc:14377","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_a8fa9dcb-1cc6-43a2-8f86-e6cea0e6fce2-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}